An Immunomodulatory Gallotanin-Rich Fraction From Caesalpinia spinosa Enhances the Therapeutic Effect of Anti-PD-L1 in Melanoma

Neoadjuvant checkpoint blockade for cancer immunotherapy

(2020) Suzanne L. Topalian et al.   SCIENCE

Polyphenols as Immunomodulatory Compounds in the Tumor Microenvironment: Friends or Foes?

(2019) Chiara Focaccetti et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Current Perspectives in Cancer Immunotherapy

(2019) Theodoulakis Christofi et al.   Cancers

Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy

(2019) Devesh Tewari et al.   SEMINARS IN CANCER BIOLOGY

Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression

(2018) Heng Lin et al.   JOURNAL OF CLINICAL INVESTIGATION

Upregulation of PD‑L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300‑mediated NF‑κB signaling

(2018) Justin Lucas et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Prophylactic vs. Therapeutic Treatment With P2Et Polyphenol-Rich Extract Has Opposite Effects on Tumor Growth

(2018) Paola Lasso et al.   Frontiers in Oncology

Apigenin suppresses PD-L1 expression in melanoma and host dendritic cells to elicit synergistic therapeutic effects

(2018) Lu Xu et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer

(2018) Peter Schmid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti–PD-L1)

(2018) Marcin Kowanetz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent

(2018) Chloé Grasselly et al.   Frontiers in Immunology

The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines

(2017) Toshifumi Doi et al.   ONCOLOGY REPORTS

Bisdemethoxycurcumin in combination with α-PD-L1 antibody boosts immune response against bladder cancer

(2017) Yiqun Shao et al.   OncoTargets and Therapy

Standardized Extract from Caesalpinia spinosa is Cytotoxic Over Cancer Stem Cells and Enhance Anticancer Activity of Doxorubicin

(2016) Tito A. Sandoval et al.   AMERICAN JOURNAL OF CHINESE MEDICINE

Cancer immunotherapy: the beginning of the end of cancer?

(2016) Sofia Farkona et al.   BMC Medicine

Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade

(2016) Joseph L. Benci et al.   CELL

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival

(2016) Jan Budczies et al.   GENES CHROMOSOMES & CANCER

Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model

(2016) Yao Lu et al.   MOLECULAR THERAPY

Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology

(2016) Mark J. Selby et al.   PLoS One

Immune-system-dependent anti-tumor activity of a plant-derived polyphenol rich fraction in a melanoma mouse model

(2016) A Gomez-Cadena et al.   Cell Death & Disease

The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status

(2016) Giuseppe Bronte et al.   Oncotarget

Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness

(2016) L. D. Miller et al.   Cancer Immunology Research

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Multifunctional T Lymphocytes Generated After Therapy With an Antitumor Gallotanin-Rich Normalized Fraction Are Related to Primary Tumor Size Reduction in a Breast Cancer Model

(2015) Claudia Urueña et al.   INTEGRATIVE CANCER THERAPIES

The Role of Cytokines in Breast Cancer Development and Progression

(2015) Marcela Esquivel-Velázquez et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma

(2015) Jason J. Luke et al.   Oncotarget

Th17 Cell Plasticity and Functions in Cancer Immunity

(2015) Leslie Guéry et al.   Biomed Research International

Programmed death-1 pathway in cancer and autoimmunity

(2014) Ariel Pedoeem et al.   CLINICAL IMMUNOLOGY

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

Gallotannin-rich Caesalpinia spinosa fraction decreases the primary tumor and factors associated with poor prognosis in a murine breast cancer model

(2013) Claudia Urueña et al.   BMC Complementary and Alternative Medicine

Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells

(2013) G. Santilli et al.   CLINICAL CANCER RESEARCH

Increased Th17 Cells in the Tumor Microenvironment Is Mediated by IL-23 via Tumor-Secreted Prostaglandin E2

(2013) X. Qian et al.   JOURNAL OF IMMUNOLOGY

A gallotannin-rich fraction from Caesalpinia spinosa (Molina) Kuntze displays cytotoxic activity and raises sensitivity to doxorubicin in a leukemia cell line

(2012) Diana M Castañeda et al.   BMC Complementary and Alternative Medicine

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

(2012) Suzanne L Topalian et al.   CURRENT OPINION IN IMMUNOLOGY

Interleukin-17, produced by lymphocytes, promotes tumor growth and angiogenesis in a mouse model of breast cancer

(2012) JIU-WEI DU et al.   Molecular Medicine Reports

The secret ally: immunostimulation by anticancer drugs

(2012) Lorenzo Galluzzi et al.   NATURE REVIEWS DRUG DISCOVERY

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

Curcumin Induces the Differentiation of Myeloid-Derived Suppressor Cells and Inhibits Their Interaction with Cancer Cells and Related Tumor Growth

(2011) S. P. Tu et al.   Cancer Prevention Research

Immunological Variation Between Inbred Laboratory Mouse Strains

(2011) R. S. Sellers et al.   VETERINARY PATHOLOGY

IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway

(2009) Lin Wang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

(2008) C A Crane et al.   ONCOGENE